

27-28
November
2020

JOIN THE DIGITAL LECTURES OF
**MIGRAINE MANAGEMENT
– LOOKING AHEAD**

THE 2ND NORDIC MIGRAINE SYMPOSIUM

Teva Nordic and the steering committee invite you as
healthcare personell to join the interactive livestream sessions
of the Nordic Migraine Symposium 2020



For registration* and more information, go to
WWW.NORDICMIGRAINESYMPOSIUM.COM

Deadline for registration is 25th November 2020

The topics and speakers have been selected by a Steering Committee consisting of leading migraine experts from the Nordic countries. The Steering Committee consists of:



Messoud Ashina
*Professor of Neurology at
Rigshospitalet Glostrup, Denmark.*



Anne Christine Poole
*General practitioner and headache
specialist at Oslo Headache Centre,
Norway.*



Mikko Kallela
*Assistant Professor, Neurology
specialist at Helsinki University
Central Hospital and Helsinki
Headache Center, Finland.*



Mattias Linde
*Professor of Neurology in the
Department of Neuroscience,
Norwegian University of Science
and Technology, Director of Tjörn Head-
ache Clinic, Sweden.*

* Registration needed to receive link to livestream
and access to the interactive symposium app

PROGRAMME; MIGRAINE MANAGEMENT – LOOKING AHEAD

All times is CET. The programme can be subject to change.

13.05-13.10		WELCOME TO NMS 2020 - DAY 1 <i>Speaker: Anne Christine Poole</i>
13.10	<i>Moderator: Messoud Ashina</i>	SESSION 1: FUTURE OF MIGRAINE MANAGEMENT
13.10-13.30		Unmet needs in migraine management <i>Speaker: Jan Versijpt</i>
13.30-13.50		Calcitonin family of peptides in migraine – beyond the CGRP <i>Speaker: Hashmat Ghanizada</i>
13.50-14.10		Role of ion channels in the trigeminal system <i>Speaker: Lars Edvinsson</i>
14.10-14.30		Discussion
14.30-14.50		Break
14.50	<i>Moderator: Marja-Liisa Sumelahti</i>	SESSION 2: MEDICATION OVERUSE AND ANTI-CGRP MABS (TWO VIEWS)
14.50-15.10		Migraine patients with MO can be treated with anti-CGRP mAbs <i>without</i> withdrawal <i>Speaker: Hans-Christoph Diener</i>
15.10-15.30		Migraine patients with MO can be treated with anti-CGRP mAbs <i>after</i> withdrawal <i>Speaker: Rigmor Jensen</i>
15.30-15.50		Discussion
15.50-16.20		Break
16.20	<i>Moderator: Mattias Linde</i>	SESSION 3: CASE REPORTS – RISK FACTORS FOR ANTI-CGRP TARGETING TREATMENTS
16.20-16.30		Cardiovascular disease <i>Speaker: Marja-Liisa Sumelahti</i>
16.30-16.40		Comorbidity of migraine and epilepsy: a case report <i>Speaker: Annelies Van Dycke</i>
16.40-16.50		Pregnancy and lactation <i>Speaker: Anne Christine Poole</i>
16.40-16.50		Wrap up and discussion day 1

9.00-9.05		WELCOME TO NMS 2020 - DAY 2 <i>Speaker: Anne Christine Poole</i>
9.05	<i>Moderator: Anne Christine Poole</i>	SESSION 4: MIGRAINE IN WOMEN
9.05-9.25		Pharmacology of monoclonal antibodies and gepants <i>Speaker: Eili Tranheim Kase</i>
9.25-9.45		Migraine management during pregnancy and lactation <i>Speaker: Mattias Linde</i>
9.45-10.05		Discussion
10.05-10.30		Break
10.30	<i>Moderator: Messoud Ashina</i>	SESSION 5: CHALLENGES USING ANTI-CGRP TREATMENT
10.30-10.50		Current preventative migraine treatments and the risk of infections <i>Speaker: Marja-Liisa Sumelahti</i>
10.50-11.10		Follow up of migraine treatment in the days of pandemic outbreak - is telehealth the answer? <i>Speaker: Gurdal Sahin</i>
11.10-11.30		Discussion
11.30-11.50		Break
11.50	<i>Moderator: Anne Christine Poole</i>	SESSION 6: NORDIC REIMBURSEMENT GUIDELINES FOR ANTI-CGRP TREATMENT
11.50-12.10		Finland: Marja-Liisa Sumelahti Denmark: Lars Bendtsen Sweden: Ingela Nilsson-Remahl Norway: Lars Jacob Stovner
12.10-12.30		Discussion
12.30		Wrap up

Any questions?

If you have any questions related to Nordic Migraine Symposium please contact your local Teva representative or the organizers directly by our website: www.nordicmigrainesymposium.com/contact